Navigation Links
Vanda Pharmaceuticals to Present Data on Iloperidone at the 2007,American Psychiatric Association Annual Meeting

ROCKVILLE, Md., May 18, 2007 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. announced today that it will present four posters on iloperidone at the 160th American Psychiatric Association (APA) annual meeting which will be held at the San Diego Convention Center in San Diego, CA, from May 19 through May 24, 2007.

The following posters will be presented on May 22, 2007, 12:00 to 2:00 p.m. PDT, in the San Diego Convention Center (Sails Pavilion, Upper Level).

POSTER NR475 - Changes in Akathisia with Iloperidone, Risperidone, or Placebo Over the Course of an Acute Efficacy Trial (Peter Weiden, M.D. and Curt Wolfgang, Ph.D.)

POSTER NR476 - Iloperidone is Well Tolerated by Subjects with Renal or Hepatic Impairment in Single-Dose Clinical Pharmacokinetic Studies (Greg Sedek, M.D., Ph.D. and Curt Wolfgang, Ph.D.)

POSTER NR507 - A Pharmacokinetic (PK)-Pharmacodynamic (PD) Relationship Exists for Efficacy of Iloperidone, a Novel Investigational Atypical Antipsychotic Agent (Paolo Baroldi, M.D., Ph.D. and Curt Wolfgang, Ph.D.)

POSTER NR508 - Genotyping Facilitates Individualized Prediction of Pharmacokinetic Exposure of Iloperidone in Extensive and Poor CYP2D6 Metabolizers (Curt Wolfgang, Ph.D.)

ABOUT VANDA PHARMACEUTICALS INC.:

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. The company has three product candidates in clinical development. Vanda's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia and bipolar disorder and has recently completed its Phase III program in schizophrenia. Vanda's second product candidate, VEC-162, is a compound for the treatment of sleep and mood disorders which is currently in Phase III for insomnia. Vanda's third product candidate, VSF-173, is a compound for the treatmen t of excessive sleepiness that is in a Phase II clinical trial. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.

CONTACT: Steven A. Shallcross, Senior Vice President, Chief FinancialOfficer of Vanda Pharmaceuticals Inc., +1-240-599-4500, steven.shallcross@vandapharma.com

Web site: http://www.vandapharma.com//

Ticker Symbol: (NASDAQ-NMS:VNDA)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Vanda Pharmaceuticals To Present Data on VEC-162 at SLEEP 2007, the Annual Meeting of the Associated Professional Sleep Societies
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016  Collagen Matrix, Inc., ("Collagen Matrix") the ... of collagen and mineral based medical devices for ... Bill Messer has joined the company as ... the growing portfolio of oral surgery, neurosurgery, orthopaedic ... joins the Collagen Matrix executive team as an ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from ... at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center ... care topics including advance care planning, healthcare costs and patient and family engagement. ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... ... Haute Living, is proud to recognize Dr. Barry M. Weintraub as a prominent ... “the most beautiful women in the world, and the most handsome men, look ...
Breaking Medicine News(10 mins):